Remote Digital Cognitive Assessment in a Trial-Ready Alzheimer’s Cohort: A Scalable Approach for Early Intervention Studies
Background: Early detection of cognitive decline in Alzheimer’s disease (AD), particularly in preclinical stages, is critical for evaluating therapeutic interventions. Traditional cognitive assessments often lack reliability and require lengthy in-person visits, limiting scalability for younger, trial-ready populations.Objectives: To evaluate the feasibility, reliability, and validity of high-frequency remote digital cognitive assessments in individuals with autosomal dominant Alzheimer’s disease (ADAD).Participants: 162 mutation carriers and non-carriers from DIAN-TU from 20 international sites (Ages 19-69 years).Measurements: Participants completed remote assessments via personal smartphones, prompted four times daily for seven days (approximately 3 minutes per session), and conventional in-clinic cognitive testing at baseline. Adherence, test–retest reliability (intraclass correlation coefficients [ICCs]), construct validity (confirmatory factor analysis), and sensitivity to clinical impairment were evaluated.Results: Average adherence was 41%. Despite this, remote measures demonstrated excellent reliability (ICCs > 0.90 after 10 sessions) and strong construct validity, with tasks loading onto memory, attention, and executive function domains. Model fit was poorer in symptomatic individuals (CDR > 0), consistent with cognitive dedifferentiation during disease progression. Both remote and traditional composites were sensitive to clinical impairment, with similar effect sizes and increasing group differences near expected symptom onset.Conclusions: High-frequency remote cognitive assessment is feasible, reliable, and valid in a relatively young international ADAD cohort. This approach offers substantial advantages for clinical trials, including reduced participant burden, improved accessibility, and enhanced reliability, supporting its integration into early-intervention studies.
Authors
- Tammie L.S. Benzinger (ORCID: https://orcid.org/0000-0002-8114-0552)
- Matthew S. Welhaf (ORCID: https://orcid.org/0000-0002-2826-5268)
- Alan E. Renton (ORCID: https://orcid.org/0000-0001-6702-8268)
- Richard J. Perrin (ORCID: https://orcid.org/0000-0002-3443-7716)
- Yan Li (ORCID: https://orcid.org/0000-0001-9382-4022)
- Randall John Bateman (ORCID: https://orcid.org/0000-0002-7729-1702)
- Sarah H. Stout (ORCID: https://orcid.org/0000-0002-8125-4912)
- David Fernando Aguillon (ORCID: https://orcid.org/0000-0003-2283-536X)
- Johannes Levin (ORCID: https://orcid.org/0000-0001-5092-4306)
- Jacob Bechara
- William S. Brooks (ORCID: https://orcid.org/0000-0001-8603-4233)
- Raquel Sánchez‐Valle (ORCID: https://orcid.org/0000-0001-7750-896X)
- Jason J. Hassenstab (ORCID: https://orcid.org/0000-0002-7802-3371)
- Suman Jayadev (ORCID: https://orcid.org/0000-0003-3164-9665)
- Ricardo Allegri (ORCID: https://orcid.org/0000-0001-7166-1234)
- Eric McDade (ORCID: https://orcid.org/0000-0002-6764-3866)
- Catherine J. Mummery (ORCID: https://orcid.org/0000-0002-6739-0803)
- Guoqiao Wang
- Martin J. Sliwinski (ORCID: https://orcid.org/0000-0002-9611-7558)
- Hannah Wilks (ORCID: https://orcid.org/0000-0001-5101-489X)
- Andrew J. Aschenbrenner (ORCID: https://orcid.org/0000-0002-4317-7282)
- Brian A. Gordon (ORCID: https://orcid.org/0000-0003-2109-2955)
- Christopher H. van Dyck
- Chengjie Xiong (ORCID: https://orcid.org/0009-0003-8949-2629)
- Samhita Katteri
Institutions
- Washington University in St. Louis (US)
Publication Details
- Published
- 2025-10-03
- DOI
- https://doi.org/10.31234/osf.io/mz62t_v1
- Primary Topic
- Cognitive Science and Mapping
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Foundation for the National Institutes of Health
- Alzheimer's Association
- Eli Lilly and Company
- GHR Foundation
- National Institutes of Health
- Avid Radiopharmaceuticals
- Janssen Pharmaceuticals